Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737110 | 0.89 | — | — | |
| SCHEMBL27793841 | 0.82 | MEN1 (0.41) | L3MBTL1ALDH1A1HSD17B10TSHRNOS1 | |
| SCHEMBL4911969 | 0.79 | L3MBTL1 (0.49) | L3MBTL1FBP1PKM | |
| SCHEMBL15547487 | 0.79 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1HSD17B10TSHRNOS1 | |
| SCHEMBL11057989 | 0.76 | HSD17B10 (0.35) | L3MBTL1ALDH1A1HSD17B10FBP1PDK1 | |
| SCHEMBL9370817 | 0.75 | KDM1A (0.40) | L3MBTL1ALDH1A1HSD17B10TSHRNOS1 | |
| SCHEMBL11058000 | 0.73 | ALDH1A1 (0.34) | ALDH1A1HSD17B10TSHRNOS1FDPS | |
| SCHEMBL9906033 | 0.72 | TDP1 (0.39) | ALDH1A1HSD17B10TSHRNOS1FBP1 | |
| SCHEMBL27572587 | 0.72 | PLA2G4A (0.50) | L3MBTL1LMNA | |
| SCHEMBL3626364 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169671-B1 | 1-(5-(TERT.-BUTYL)ISOXAZOL-3-YL)-3-(4-((PHENYL)ETHYNYL)PHENYL)UREA DERIVATIVES AND RELATED COMPOUNDS AS FLT3 INHIBITORS FOR TREATING CANCER | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2875001-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-10065934-B2 | Substituted urea derivatives and pharmaceutical uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-04 | — | — | US | disclosed |
| EP-3169671-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| WO-2016008433-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-01-21 | — | — | WO | disclosed |
| EP-2875001-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-05-27 | — | — | EP | disclosed |
| WO-2015043492-A1 | SUBSTITUTED UREA DERIVATIVES AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-04-02 | — | — | WO | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| WO-2014012360-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-01-23 | — | — | WO | disclosed |
| US-5077288-A | Adrenergic, serotonin and histamine antagonist | ADIR ET COMPAGNIE (FR) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | L3MBTL1 3927/4885ALDH1A1 1530/4885HSD17B10 3456/4885 |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ULK2, ULK3, ULK1 | L3MBTL1 4521/4885ALDH1A1 2900/4885HSD17B10 4007/4885 |
| US-10065934-B2 | Substituted urea derivatives and pharmaceutical uses thereof | ULK2, ULK3, ULK1 | L3MBTL1 4521/4885ALDH1A1 2900/4885HSD17B10 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.